In the TOGETHER-PsO trial, 27% of patients on ixekizumab plus tirzepatide achieved complete skin clearance and at least 10% weight loss at 36 weeks.
2
The combination therapy met the primary endpoint, showing superiority over ixekizumab monotherapy in achieving skin clearance and weight reduction.
3
A key secondary analysis revealed 41% of the combination group achieved Psoriasis Area and Severity Index 100, a 40% relative increase over monotherapy.
4
The trial enrolled 274 adults with moderate-to-severe plaque psoriasis and obesity, with a mean BMI greater than 39 kg/m².
5
Adverse events from the combination therapy were mild to moderate, with nausea and diarrhea being the most reported side effects.
